Veterinary Medicines Directorate

Woodham Lane, New Haw, Addlestone, Surrey KT15 3LS
Telephone +44 (0)1932 336911

Post Authorisation Assessments

Quiflor Multi 100 mg/ml Solution for Injection for Cattle and Pigs (Sows)

Vm 01656/4055

08 April 2026	Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV).
08 March 2026	Submission of a Ph. Eur. CEP for an active substance.
10 February 2026	Deleting of a manufacturer of the active substance.
29 September 2025	Change of Distributor from: Alloga UK Limited, Amber Park, Berristow Lane, South Normanton, Alfreton, Derbyshire, DE55 2FH to KRKA UK Ltd, Thames House, Waterside Drive, Langley, SL3 6EZ, United Kingdom
28 July 2025	Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State to reflect compliance with the Ph. Eur. by removing reference to the internal test method and test method number.
02 March 2022	Submission of a new Ph. Eur. certificate of suitability for an active substance.
15 February 2022	Minor changes to an approved test procedure of the finished product.
20 December 2018	Change of distributor details, from Zoetis UK Limited, 5th Floor, 6 St. Andrew Street, London, EC4A 3AE to Alloga UK Limited, Centaur Services Limited, National veterinary Services Limited, Henry Schein UK Holdings Limited. Changes to the labelling and package leaflet. Change in local representative.
20 December 2018	Change in the invented name of the veterinary medicinal product from Ubiflox to Quiflor Multi.
02 August 2016	Extension of retest period of active substance.
09 June 2016	Renewal – UK as RMS
20 May 2015	Change in manufacturing site of the active substance.
25 November 2013	Change of distributor.
05 April 2013	Extension of shelf life of finished product from 2 to 3 years.
08 February 2013	Addition of a third route of synthesis (ROS3) for the active substance and deletion of a manufacturing site for ROS1.
06 December 2012	Change in the QPPV of an existing pharmacovigilance system as described in the DDPS .
20 September 2012	Addition of a new withdrawal period. To add an additional indication. To add an additional dosage regimen.
25 July 2012	To change the MAH (from Milklich Laboratorios to Krka,

	d.d) and Vm numbers.